193 related articles for article (PubMed ID: 23937231)
21. The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity.
Tian Y; Wu LH; Oxender DL; Chung FZ
J Biol Chem; 1996 Aug; 271(34):20250-7. PubMed ID: 8702757
[TBL] [Abstract][Full Text] [Related]
22. Chimeric NK1 (substance P)/NK3 (neurokinin B) receptors. Identification of domains determining the binding specificity of tachykinin agonists.
Gether U; Johansen TE; Schwartz TW
J Biol Chem; 1993 Apr; 268(11):7893-8. PubMed ID: 7681831
[TBL] [Abstract][Full Text] [Related]
23. Functional characterisation of tachykinin receptors mediating ion transport in porcine jejunum.
Thorbøll JE; Bindslev N; Hansen MB; Schmidt P; Skadhauge E
Eur J Pharmacol; 1998 Oct; 359(2-3):271-9. PubMed ID: 9832399
[TBL] [Abstract][Full Text] [Related]
24. Tachykinin receptors on human monocytes: their involvement in rheumatoid arthritis.
Brunelleschi S; Bordin G; Colangelo D; Viano I
Neuropeptides; 1998 Jun; 32(3):215-23. PubMed ID: 10189055
[TBL] [Abstract][Full Text] [Related]
25. Modulation of excitatory amino acid responses by tachykinins and selective tachykinin receptor agonists in the rat spinal cord.
Cumberbatch MJ; Chizh BA; Headley PM
Br J Pharmacol; 1995 Jul; 115(6):1005-12. PubMed ID: 7582496
[TBL] [Abstract][Full Text] [Related]
26. Tachykinin receptors and receptor subtypes.
Patacchini R; Maggi CA
Arch Int Pharmacodyn Ther; 1995; 329(1):161-84. PubMed ID: 7639617
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
[TBL] [Abstract][Full Text] [Related]
28. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice.
Teixeira RM; Santos AR; Ribeiro SJ; Calixto JB; Rae GA; De Lima TC
Eur J Pharmacol; 1996 Sep; 311(1):7-14. PubMed ID: 8884230
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the tachykinin receptors involved in spinal and supraspinal cardiovascular regulation.
Couture R; Picard P; Poulat P; Prat A
Can J Physiol Pharmacol; 1995 Jul; 73(7):892-902. PubMed ID: 8846427
[TBL] [Abstract][Full Text] [Related]
30. Tachykinin receptors in rabbit airways--characterization by functional, autoradiographic and binding studies.
Black JL; Diment LM; Alouan LA; Johnson PR; Armour CL; Badgery-Parker T; Burcher E
Br J Pharmacol; 1992 Oct; 107(2):429-36. PubMed ID: 1384914
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological assessment of spantide II analogues.
Wang ZY; Feng DM; Wang YL; Tung SR; Wong K; Strichartz GR; Folkers K; Håkanson R
Eur J Pharmacol; 1994 Aug; 260(2-3):121-8. PubMed ID: 7527343
[TBL] [Abstract][Full Text] [Related]
32. Facilitatory effects of selective agonists for tachykinin receptors on cholinergic neurotransmission: evidence for species differences.
Belvisi MG; Patacchini R; Barnes PJ; Maggi CA
Br J Pharmacol; 1994 Jan; 111(1):103-10. PubMed ID: 7516799
[TBL] [Abstract][Full Text] [Related]
33. Tachykinins increase [3H]acetylcholine release in mouse striatum through multiple receptor subtypes.
Preston Z; Lee K; Widdowson L; Richardson PJ; Pinnock RD
Neuroscience; 2000; 95(2):367-76. PubMed ID: 10658616
[TBL] [Abstract][Full Text] [Related]
34. Respiratory actions of tachykinins in the nucleus of the solitary tract: characterization of receptors using selective agonists and antagonists.
Mazzone SB; Geraghty DP
Br J Pharmacol; 2000 Mar; 129(6):1121-31. PubMed ID: 10725260
[TBL] [Abstract][Full Text] [Related]
35. Adaptive plasticity in tachykinin and tachykinin receptor expression after focal cerebral ischemia is differentially linked to gabaergic and glutamatergic cerebrocortical circuits and cerebrovenular endothelium.
Stumm R; Culmsee C; Schafer MK; Krieglstein J; Weihe E
J Neurosci; 2001 Feb; 21(3):798-811. PubMed ID: 11157066
[TBL] [Abstract][Full Text] [Related]
36. Analysis of C-terminally substituted tachykinin-like peptide agonists by means of aequorin-based luminescent assays for human and insect neurokinin receptors.
Torfs H; Detheux M; Oonk HB; Akerman KE; Poels J; Van Loy T; De Loof A; Vassart G; Parmentier M; Vanden Broeck J
Biochem Pharmacol; 2002 May; 63(9):1675-82. PubMed ID: 12007570
[TBL] [Abstract][Full Text] [Related]
37. NK2 receptors mediate tachykinin-induced contractions of rat uterus during the oestrous cycle.
Moodley N; Lau WA; Pennefather JN; Story ME; Fisher L
Eur J Pharmacol; 1999 Jul; 376(1-2):53-60. PubMed ID: 10440089
[TBL] [Abstract][Full Text] [Related]
38. Postnatal development of NK1, NK2, and NK3 neurokinin receptors expression in the rat retina.
Oyamada H; Takatsuji K; Senba E; Mantyh PW; Tohyama M
Brain Res Dev Brain Res; 1999 Oct; 117(1):59-70. PubMed ID: 10536233
[TBL] [Abstract][Full Text] [Related]
39. Tachykinin NK3 and NK1 receptor activation elicits secretion from porcine airway submucosal glands.
Phillips JE; Hey JA; Corboz MR
Br J Pharmacol; 2003 Jan; 138(1):254-60. PubMed ID: 12522097
[TBL] [Abstract][Full Text] [Related]
40. Comparison of tachykinin NK1 and NK2 receptors in the circular muscle of the guinea-pig ileum and proximal colon.
Maggi CA; Patacchini R; Meini S; Quartara L; Sisto A; Potier E; Giuliani S; Giachetti A
Br J Pharmacol; 1994 May; 112(1):150-60. PubMed ID: 7518302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
